RSV cps2 Vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Respiratory Syncytial Virus Infections

Phase 1

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

CompletedNCT01852266

National Institute of Allergy and Infectious Diseases (NIAID)Respiratory Syncytial Virus Infections

Start: 2013-10-31Updated: 2016-09-15

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

CompletedNCT01968083

National Institute of Allergy and Infectious Diseases (NIAID)Respiratory Syncytial Virus Infections

Start: 2013-10-03End: 2015-05-31Updated: 2021-07-26

Related Papers

Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children

The Journal of Infectious Diseases2018-01-2959 citations